Repligen Corporation (RGEN) P/E Ratio History
UndervaluedTrading at 162.6x vs 5Y avg 552.9x · 60th percentile · Below historical baseline · Data 2005–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Repligen Corporation (RGEN) trades at a price-to-earnings ratio of 162.6x, with a stock price of $139.83 and trailing twelve-month earnings per share of $0.91.
The current P/E is 71% below its 5-year average of 552.9x. Over the past five years, RGEN's P/E has ranged from a low of 52.3x to a high of 6683.5x, placing the current valuation at the 60th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, RGEN trades at a 596% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, RGEN commands a significant premium over the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RGEN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
RGEN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
RGEN P/E vs Peers
Diagnostics and life science tools peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 11.4Lowest | -Best | +68%Best | |
| $13B | 58.2 | -Best | -70% | |
| $13B | 53.9 | -Best | -14% | |
| $11B | 154.3 | -Best | -56% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
RGEN Historical P/E Data (2005–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $117.82 | $0.90 | 130.9x | -45% |
| FY2025 Q4 | Dec 31 2025 | $163.86 | $0.85 | 192.8x | -20% |
| FY2025 Q3 | - | $133.67 | $0.02 | 6683.5x | +2685% |
| FY2025 Q2 | Jun 30 2025 | $124.38 | $0.08 | 1554.8x | +548% |
| FY2024 Q1 | Mar 31 2024 | $183.92 | $0.25 | 735.7x | +207% |
| FY2023 Q4 | Dec 31 2023 | $179.80 | $0.72 | 249.7x | +4% |
| FY2023 Q3 | Sep 30 2023 | $159.01 | $2.03 | 78.3x | -67% |
| FY2023 Q2 | Jun 30 2023 | $141.46 | $2.42 | 58.5x | -76% |
| FY2023 Q1 | Mar 31 2023 | $168.36 | $2.95 | 57.1x | -76% |
| FY2022 Q4 | Dec 31 2022 | $169.31 | $3.24 | 52.3x | -78% |
| FY2022 Q3 | Sep 30 2022 | $187.11 | $2.89 | 64.7x | -73% |
| FY2022 Q2 | - | $162.40 | $2.76 | 58.8x | -75% |
| FY2022 Q1 | - | $188.09 | $2.52 | 74.6x | -69% |
| FY2021 Q4 | Dec 31 2021 | $264.84 | $2.24 | 118.2x | -51% |
| FY2021 Q3 | - | $288.99 | $2.10 | 137.6x | -43% |
| FY2021 Q2 | Jun 30 2021 | $199.62 | $1.79 | 111.5x | -54% |
| FY2021 Q1 | Mar 31 2021 | $194.41 | $1.45 | 134.1x | -44% |
| FY2020 Q4 | - | $191.63 | $1.11 | 172.6x | -28% |
| FY2020 Q3 | Sep 30 2020 | $147.54 | $0.82 | 179.9x | -25% |
| FY2020 Q2 | - | $123.61 | $0.58 | 213.1x | -11% |
| FY2020 Q1 | - | $96.54 | $0.45 | 214.5x | -11% |
| FY2019 Q4 | - | $92.50 | $0.44 | 210.2x | -12% |
| FY2019 Q3 | Sep 30 2019 | $76.69 | $0.49 | 156.5x | -35% |
| FY2019 Q2 | Jun 30 2019 | $85.95 | $0.56 | 153.5x | -36% |
| FY2019 Q1 | Mar 31 2019 | $59.08 | $0.45 | 131.3x | -45% |
| FY2018 Q4 | Dec 31 2018 | $52.74 | $0.36 | 146.5x | -39% |
| FY2018 Q3 | Sep 30 2018 | $55.46 | $0.51 | 108.7x | -55% |
| FY2018 Q2 | Jun 30 2018 | $47.04 | $0.52 | 90.5x | -62% |
| FY2018 Q1 | Mar 31 2018 | $36.18 | $0.70 | 51.7x | -78% |
| FY2017 Q4 | Dec 31 2017 | $36.28 | $0.71 | 51.1x | -79% |
| FY2017 Q3 | Sep 30 2017 | $38.32 | $0.59 | 64.9x | -73% |
| FY2017 Q2 | Jun 30 2017 | $41.44 | $0.51 | 81.3x | -66% |
| FY2017 Q1 | Mar 31 2017 | $35.20 | $0.38 | 92.6x | -61% |
| FY2016 Q4 | Dec 31 2016 | $30.82 | $0.34 | 90.6x | -62% |
| FY2016 Q3 | Sep 30 2016 | $30.19 | $0.20 | 150.9x | -37% |
| FY2016 Q2 | - | $27.36 | $0.25 | 109.4x | -54% |
| FY2016 Q1 | - | $26.82 | $0.25 | 107.3x | -55% |
| FY2015 Q4 | - | $28.29 | $0.29 | 97.6x | -59% |
| FY2015 Q3 | Sep 30 2015 | $27.85 | $0.27 | 103.9x | -57% |
| FY2015 Q2 | - | $41.27 | $0.23 | 180.9x | -25% |
| FY2015 Q1 | - | $30.36 | $0.21 | 145.9x | -39% |
| FY2014 Q4 | Dec 31 2014 | $19.80 | $0.25 | 79.8x | -67% |
| FY2014 Q3 | - | $19.91 | $0.36 | 55.3x | -77% |
| FY2014 Q2 | Jun 30 2014 | $22.79 | $0.50 | 45.6x | -81% |
| FY2014 Q1 | Mar 31 2014 | $12.86 | $0.55 | 23.4x | -90% |
| FY2013 Q4 | - | $13.64 | $0.49 | 27.8x | -88% |
| FY2013 Q3 | Sep 30 2013 | $11.09 | $0.69 | 16.1x | -93% |
| FY2013 Q2 | Jun 30 2013 | $8.24 | $0.57 | 14.5x | -94% |
| FY2013 Q1 | Mar 31 2013 | $6.91 | $0.48 | 14.4x | -94% |
| FY2012 Q4 | Dec 31 2012 | $6.28 | $0.45 | 14.0x | -94% |
| FY2012 Q3 | Sep 30 2012 | $5.96 | $0.17 | 35.1x | -85% |
| FY2012 Q2 | Jun 30 2012 | $4.30 | $0.11 | 39.7x | -83% |
| FY2010 Q4 | Dec 31 2010 | $4.69 | $0.01 | 670.0x | +179% |
| FY2009 Q1 | - | $4.79 | $0.18 | 27.0x | -89% |
| FY2008 Q4 | Dec 31 2008 | $3.78 | $0.17 | 22.9x | -90% |
| FY2008 Q3 | - | $4.71 | $0.16 | 30.1x | -87% |
| FY2008 Q2 | Jun 30 2008 | $4.72 | $1.44 | 3.3x | -99% |
| FY2008 Q1 | Mar 31 2008 | $4.82 | $1.19 | 4.0x | -98% |
| FY2007 Q4 | Dec 31 2007 | $6.55 | $1.29 | 5.1x | -98% |
| FY2007 Q3 | Sep 30 2007 | $4.33 | $1.30 | 3.3x | -99% |
| FY2006 Q1 | Mar 31 2006 | $3.70 | $0.02 | 177.9x | -26% |
| FY2005 Q4 | Dec 31 2005 | $4.00 | $0.03 | 119.0x | -50% |
| FY2005 Q3 | Sep 30 2005 | $3.12 | $0.03 | 92.0x | -62% |
Average P/E for displayed period: 240.0x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
21+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RGEN — Frequently Asked Questions
Quick answers to the most common questions about buying RGEN stock.
What is RGEN's P/E ratio?
Repligen Corporation (RGEN) trailing twelve-month P/E ratio is 162.6x, based on TTM diluted EPS of $0.91. The 5-year average P/E is 552.9x and the historical range spans 52.3x to 6683.5x.
Is RGEN stock overvalued or undervalued?
RGEN trades at 162.6x P/E, below its 5-year average of 552.9x. At the 60th percentile of its historical range (52.3x–6683.5x), the stock is priced at a discount to its own history.
Is RGEN stock expensive?
No, RGEN is not expensive on a historical basis. The current P/E of 162.6x is below the 5-year average of 552.9x and sits at the 60th percentile of its valuation range.
What is RGEN's historical P/E range?
Over the past 5 years, RGEN's P/E ratio has ranged from 52.3x to 6683.5x, with a median of 134.1x and an average of 552.9x. The current P/E of 162.6x places the stock at the 60th percentile of this range. Full historical data spans 2005–2026.
How does RGEN's P/E compare to the S&P 500?
RGEN trades at 162.6x P/E versus the S&P 500 median of 25.9x. The 528% premium to the market typically reflects higher expected earnings growth or quality.
How does RGEN's valuation compare to Healthcare peers?
Repligen Corporation P/E of 162.6x compares to the Healthcare sector median of 23.4x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is RGEN's PEG ratio?
RGEN PEG ratio is N/A, based on a P/E of 162.6x and EPS growth of 287.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is RGEN's earnings yield?
RGEN earnings yield is 0.61%, the inverse of its 162.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.